Recent trends in human milk oligosaccharides: New synthesis technology, regulatory effects, and mechanisms of non‐intestinal functions

Abstract Recently, the non‐intestinal functions of human milk oligosaccharides (HMOs) have been widely documented, including their roles in promoting brain development and growth, as well as ameliorating anxiety, allergies, and obesity. Understanding their mechanisms of action is becoming increasingly critical. Furthermore, these effects are frequently associated with the type and structure of HMOs. As an innovative technology, “plant factory” is expected to complement traditional synthesis technology. This study reviews the novel “plant factory” synthesis techniques. Particular emphasis is placed on the processes, advantages, and limitations of “plant factory” synthesis of HMOs. This technology can express genes related to HMO synthesis instantaneously in plant leaves, thereby enabling the rapid and cost‐effective generation of HMOs. However, “plant factory” technology remains underdeveloped, and challenges related to low yield and unsustainable production must be addressed. Furthermore, we present an overview of the most recent clinical and preclinical studies on the non‐intestinal functions of HMOs. This review emphasizes the mechanisms of action underlying the non‐intestinal functions of HMOs. HMOs primarily exert non‐intestinal functions through the cleavage of beneficial monomer components, metabolism to produce advantageous metabolites, and regulation of immune responses.